=Teva Pharma (TEVA) reported earnings Thur 4 Aug 2016 (b/o)

Teva Pharma beats raised expectations; reaffirms FY16 EPS guidance, revs guidance  :

• Reports Q2 (Jun) earnings of $1.25 per share, $0.04 better than the Capital IQ Consensus of $1.21; revenues rose 1.4% year/year to $5.04 bln vs the $4.88 bln Capital IQ Consensus. 
• Preannounced: Raised Q2 EPS to $1.19-1.22 from $1.16-1.20; rev to $4.9-5.0 from $4.8-4.9 bln on July 13.
  • Generic medicines revenues in the second quarter of 2016 amounted to $2.3 billion, a decrease of 7% compared to the second quarter of 2015. generic medicines segment generated profit of $614 million in the second quarter of 2016, a decrease of 16% compared to the second quarter of 2015.
  • Specialty medicines revenues in the second quarter of 2016 amounted to $2.3 billion, an increase of 9% compared to the second quarter of 2015. Global revenues of Copaxone (20 mg/mL and 40 mg/mL), the leading multiple sclerosis therapy in the U.S. and globally, amounted to $1.1 billion, an increase of 8% compared to the second quarter of 2015.
• Co reaffirms guidance for FY16, sees EPS of $5.20-5.40 vs. $5.26 Capital IQ Consensus Estimate; sees FY16 revs of $22.0-22.5 bln vs. $22.25 bln Capital IQ Consensus Estimate.